Professional
Added to YB: 2024-05-02
Pitch date: 2024-04-24
ROIV [bullish]
Roivant Sciences Ltd.
+103.15%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Market Cap
$14.1B
Pitch Price
$10.78
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.39
P/E
-20.20
EV/Sales
505.07
Sector
Biotechnology
Category
value
Show full summary:
Greenlight Capital New Portfolio Holding: Roivant Sciences Ltd.
ROIV: Biotech w/ $6B cash, $2.6B IMVT stake, market cap only $9B. Potentially owed billions in COVID vax royalties from MRNA & PFE. Ph2 autoimmune drug & topical for psoriasis/eczema are multi-B$ opps. Other early stage assets & biz dev to unlock value. $1.5B buyback. Bought at $10.96.
Read full article (1 min)